Could Viking Therapeutics Next: Will It Challenge Lilly?
The race to own the GLP-1 weight loss market has a new challenger in Viking Therapeutics. This article breaks down wh...
This guide highlights common missteps when crafting a budget and offers practical alternatives to keep you on track and aligned with goals.
26,436 articlesThe race to own the GLP-1 weight loss market has a new challenger in Viking Therapeutics. This article breaks down wh...
SoFi has surprised some investors by turning a key profitability metric into a clear strength. This article breaks do...
As AI rivals surge and cloud demand shifts, investors question Microsoft’s staying power in the Magnificent 7. The de...
A veteran investor recounts how being wrong about inflation missed a powerful stock rally and details a straightforwa...
Reddit has grown from a discussion board to a major online community with monetization potential. This article examin...
SpaceX going public could redefine the balance of big-name holdings in passive portfolios. This guide explains what b...
Two pharma giants are wighting for a leadership position in immunology. This piece explains why Johnson Johnson hopes...
Broadcom's AI outlook miss triggered a pronounced one-day pullback, signaling investor caution around AI-driven growt...
Lilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
SoFi Technologies popped on June trading as institutional buyers chased continued innovation. This deep dive explains...
Broadcom posted a strong quarter, but AI guidance missed whispers and the stock sold off sharply, underscoring a new ...
A single insider purchase can spark questions about a stock, but it isn’t a sure shot signal. This article digs into ...